{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:53:06Z","timestamp":1792641186761,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,6]],"date-time":"2016-09-06T00:00:00Z","timestamp":1473120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ejim.2016.07.011","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T17:58:13Z","timestamp":1470938293000},"page":"25-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe"],"prefix":"10.1016","volume":"37","author":[{"given":"Nadia","family":"Belmatoug","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Di Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lukina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Maison-Blanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Niederau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Pl\u04e7ckinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Stulnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"vom Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2016.07.011_bb0005","series-title":"Summary of product characteristics","author":"CERDELGA\u2122","year":"2014"},{"key":"10.1016\/j.ejim.2016.07.011_bb0010","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1001\/archinte.158.16.1754","article-title":"Gaucher disease: recommendations on diagnosis, evaluation, and monitoring","volume":"158","author":"Charrow","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2016.07.011_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ejim.2016.07.011_bb0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","article-title":"Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients","volume":"41","author":"Weinreb","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ejim.2016.07.011_bb0025","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ajh.21888","article-title":"A reappraisal of Gaucher disease-diagnosis and disease management algorithms","volume":"86","author":"Mistry","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2016.07.011_bb0030","article-title":"Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States","author":"Balwani","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ejim.2016.07.011_bb0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00431-003-1362-0","article-title":"Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements","volume":"163","author":"Grabowski","year":"2004","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.ejim.2016.07.011_bb0040","series-title":"OMMBID: the online metabolic and molecular bases of inherited disease","article-title":"Gaucher disease","author":"Grabowski","year":"2013"},{"key":"10.1016\/j.ejim.2016.07.011_bb0045","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","article-title":"Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis","volume":"147","author":"Mistry","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2016.07.011_bb0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","article-title":"Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults","volume":"46","author":"Mistry","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.ejim.2016.07.011_bb0055","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ymgme.2011.08.004","article-title":"Therapeutic approaches to bone pathology in Gaucher disease: past, present and future","volume":"104","author":"Goker-Alpan","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ejim.2016.07.011_bb0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1096-7192(02)00122-1","article-title":"Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy","volume":"77","author":"Mistry","year":"2002","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ejim.2016.07.011_bb0065","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s002560000276","article-title":"Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume","volume":"29","author":"Terk","year":"2000","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.ejim.2016.07.011_bb0070","first-page":"1","article-title":"Disease state awareness in Gaucher disease: a Q&a expert roundtable discussion","volume":"10","author":"Mistry","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ejim.2016.07.011_bb0075","series-title":"GeneReviews","article-title":"Gaucher disease","author":"Pastores","year":"2013"},{"key":"10.1016\/j.ejim.2016.07.011_bb0080","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5years of treatment: a report from the Gaucher registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2016.07.011_bb0085","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","article-title":"Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis","volume":"108","author":"de Fost","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2016.07.011_bb0090","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","article-title":"Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease","volume":"71","author":"Weinreb","year":"2007","journal-title":"Clin Genet"},{"key":"10.1016\/j.ejim.2016.07.011_bb0095","first-page":"1169","article-title":"Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases","volume":"11","author":"Cox","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.ejim.2016.07.011_bb0100","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease","volume":"91","author":"McEachern","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ejim.2016.07.011_bb0105","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","article-title":"Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease","volume":"35","author":"Shayman","year":"2010","journal-title":"Drugs Future"},{"key":"10.1016\/j.ejim.2016.07.011_bb0110","series-title":"Summary of product characteristics","author":"Zavesca (miglustat)","year":"2013"},{"key":"10.1016\/j.ejim.2016.07.011_bb0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/pds.3760","article-title":"Results from a 9-year intensive safety surveillance scheme in miglustat (Zavesca(R))-treated patients","volume":"24","author":"Brand","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ejim.2016.07.011_bb0120","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ejim.2016.07.011_bb0125","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","article-title":"Randomized, controlled trial of miglustat in Gaucher's disease type 3","volume":"64","author":"Schiffmann","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ejim.2016.07.011_bb0130","first-page":"S69","article-title":"Tremor and peripheral neuropathy are infrequent and non-serious events in Gaucher type 1 patients treated with eliglustat [abstract]","volume":"114","author":"Lau","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ejim.2016.07.011_bb0135","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2016.07.011_bb0140","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2016.07.011_bb0145","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2016.07.011_bb0150","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.ymgme.2014.12.179","article-title":"ENGAGE: a phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with Gaucher disease type 1: results after 18months [abstract]","volume":"114","author":"Mistry","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ejim.2016.07.011_bb0155","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4years of treatment","volume":"53","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.ejim.2016.07.011_bb0160","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2016.07.011_bb0165","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.ymgme.2014.12.058","article-title":"ENCORE, a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results [abstract]","volume":"114","author":"Cox","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ejim.2016.07.011_bb0170","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00256-014-1891-9","article-title":"Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat","volume":"43","author":"Kamath","year":"2014","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.ejim.2016.07.011_bb0175","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1124\/dmd.104.002824","article-title":"Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats","volume":"33","author":"Hidaka","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejim.2016.07.011_bb0180","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11418-008-0239-y","article-title":"Analysis of CYP3A inhibitory components of star fruit (Averrhoa carambola L.) using liquid chromatography-mass spectrometry","volume":"62","author":"Hosoi","year":"2008","journal-title":"J Nat Med"},{"key":"10.1016\/j.ejim.2016.07.011_bb0185","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1067\/mcp.2001.113185","article-title":"Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins","volume":"69","author":"Malhotra","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2016.07.011_bb0190","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/dmd.106.012724","article-title":"The in vitro drug interaction potential of dietary supplements containing multiple herbal components","volume":"35","author":"Foti","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejim.2016.07.011_bb0195","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5478\/MSL.2014.5.3.84","article-title":"In vitro inhibitory effect of licoricidin on human cytochrome P450s","volume":"5","author":"Kim","year":"2014","journal-title":"Mass Spectrosc Lett"},{"key":"10.1016\/j.ejim.2016.07.011_bb0200","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1124\/dmd.115.065987","article-title":"High-throughput cytochrome P450 cocktail inhibition assay for assessing drug\u2013drug and drug-botanical interactions","volume":"43","author":"Li","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejim.2016.07.011_bb0205","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/jog.12254","article-title":"Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease","volume":"40","author":"Elstein","year":"2014","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.ejim.2016.07.011_bb0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejogrb.2010.12.024","article-title":"The management of pregnancy in Gaucher disease","volume":"156","author":"Granovsky-Grisaru","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejim.2016.07.011_bb0215","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.clinthera.2010.11.008","article-title":"Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk","volume":"32","author":"Sekijima","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejim.2016.07.011_bb0220","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bcmd.2009.04.003","article-title":"The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause)","volume":"43","author":"Zimran","year":"2009","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.ejim.2016.07.011_bb0225","series-title":"European working group on Gaucher disease 11th meeting. Haifa, Israel","article-title":"Electrocardiographic evaluation of eliglustat: results of a thorough QT study and phase 2 and 3 clinical trials [asbtract]","author":"Ruskin","year":"2014"},{"key":"10.1016\/j.ejim.2016.07.011_bb0230","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.ymgme.2013.12.218","article-title":"Eliglustat adverse event data from a pooled analysis of four trials in Gaucher disease type 1 [abstract]","volume":"111","author":"Ross","year":"2014","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ejim.2016.07.011_bb0235","doi-asserted-by":"crossref","first-page":"e0039","DOI":"10.5041\/RMMJ.10173","article-title":"Hemorrhagic aspects of Gaucher disease","volume":"5","author":"Rosenbaum","year":"2014","journal-title":"Rambam Maimonides Med J"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620516302175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620516302175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T08:53:30Z","timestamp":1536483210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620516302175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":47,"alternative-id":["S0953620516302175"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2016.07.011","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2016.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}